Physician profile
Stuart Waldstreicher
NPI 1114913894
$5,111.23
in general payments reported to CMS, 2019-2025
24 companies · $746 in 2025
The $746 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,352 · 2020: $245 · 2021: $160 · 2022: $983 · 2023: $870 · 2024: $756 · 2025: $746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,371.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,371.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,125.42 | 2020-2025 | Rinvoq, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $791.55 | 2019-2024 | Xifaxan, Trulance |
| Pfizer INC. | $740.51 | 2019-2025 | |
| Janssen Biotech, INC. | $468.09 | 2019-2023 | Stelara, Simponi Aria, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $286.83 | 2019-2025 | Entyvio |
| Ardelyx, INC. | $248.40 | 2022-2025 | Ibsrela |
| Celgene Corporation | $228.37 | 2022-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $189.36 | 2023-2025 | Voquezna |
| Allergan, INC. | $136.85 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $129.86 | 2019-2024 | Linzess |
| Ethicon US, LLC | $120.42 | 2019 | |
| Ferring Pharmaceuticals INC. | $118.32 | 2019-2023 | Cimzia |
| Braintree Laboratories, INC. | $89.98 | 2020-2024 | Suflave, Sutab |
| Genzyme Corporation | $85.53 | 2022-2023 | |
| Gilead Sciences, INC. | $80.03 | 2019-2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $76.95 | 2023 | Cologuard Collection Kit |
| Nestle Healthcare Nutrition INC. | $72.78 | 2022-2023 | |
| Lilly USA, LLC | $39.32 | 2024 | Omvoh |
| Intra-Sana Laboratories | $20.13 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Qol Medical, LLC | $18.99 | 2025 | Sucraid |
| Intercept Pharmaceuticals, INC. | $18.09 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $14.03 | 2022 | |
| Micro-Tech Endoscopy USA, INC. | $11.42 | 2023 | Lesion Hunter |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$77,759.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Waldstreicher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.